Three Key Takeaways From Johnson & Johnson (JNJ)’s Q2

Page 1 of 2

Johnson & Johnson (NYSE:JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion. The EPS was higher than analyst estimates, and the company upped its full-year guidance.

Johnson & Johnson (NYSE:JNJ)

But the details are where things get interesting. Here are three key takeaways from the earnings report — and what they mean for Johnson & Johnson (NYSE:JNJ)’s future.

1. Infectious disease and oncology drove pharma growth

Total worldwide pharmaceuticals had a reported sales growth of 11.7% to $7.025 billion. Most of that growth came from infectious disease and oncology. Reported sales for these segments grew 23.1% and 51%, respectively.

Prostate cancer drug Zytiga was the oncology champion, growing 70.3% worldwide to $395 million. According to Johnson & Johnson (NYSE:JNJ), Zytiga now holds over 30% of the global market for metastatic castrate-resistant prostate cancer.

Zytiga received Food and Drug Administration approval in early 2011 for usage after chemotherapy. But the drug received approval late last year to become a first-line treatment. Zytiga’s second quarter growth was due to that expanded indication and the rollout of the drug into additional international markets.

The highest growth in the infectious disease segment belonged to the hepatitis C protease inhibitor Incivek, which grew 68.6% worldwide mostly due to additional international rollouts. That growth only equaled sales of $172 million for Johnson & Johnson (NYSE:JNJ) because Incivek is a partnered drug with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Johnson & Johnson (NYSE:JNJ) is on the smaller side of that deal. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s first quarter report showed Incivek’s net product revenues at $206.5 million. But these protease inhibitors will likely lose substantial market share once the all-oral HCV drugs come to market.

The more interesting infectious disease story is HIV treatment Prezista, which had 16.6% worldwide growth to $435 million. Growth was fairly consistent between the U.S. and international, and this drug has been approved for over five years. So what we’re seeing here is organic growth caused by more patients adopting the drug.

2. Stagnant device growth will improve

Worldwide device growth was only 4% for the quarter, with most segments holding steady while diabetes device sales fell. But those figures aren’t including the recently finalized Syntes merger, which brings things up to a 48.9% worldwide growth.

Johnson & Johnson (NYSE:JNJ) shelled out $21.3 billion for Syntes back in 2011. Syntes is a market leader in trauma devices including bone grafts and plates. Johnson has now merged Syntes with its previously existing DePuy subsidiary.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!